Clofarabine-induced kidney toxicity
| Autor: | Shailaja Chidella, Steven Fishbane, Steven L. Allen, Kenar D. Jhaveri |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Drug Purine media_common.quotation_subject Pharmacology chemistry.chemical_compound Adverse Event Reporting System medicine Animals Humans Clofarabine Pharmacology (medical) Adverse effect media_common Adenine Nucleotides business.industry Acute kidney injury Myeloid leukemia Acute Kidney Injury Middle Aged medicine.disease Leukemia Myeloid Acute Proteinuria Ribonucleotide reductase Oncology chemistry Arabinonucleosides business medicine.drug |
| Zdroj: | Journal of Oncology Pharmacy Practice. 20:305-308 |
| ISSN: | 1477-092X 1078-1552 |
| Popis: | Clofarabine is a purine nucleoside analog indicated for treatment of relapsed or refractory acute lymphoblastic leukaemia in children. The drug is also increasingly used, outside of its FDA approved indication, for treatment of relapsed or refractory acute myeloid leukemia in adults. It acts by inhibiting DNA synthesis, the enzyme ribonucleotide reductase and repair and activation of mitochondrial repair processes. We describe a case of a 48-year-old male with refractory acute myeloid leukemia with acute kidney injury associated with clofarabine treatment. We conducted a review of the literature and utilized the Food and Drug Administration Adverse Event Reporting System to identify spontaneous reporting of renal adverse events with this drug in 29 other cases. Since clofarabine inhibits ribonucleotide reductase, we postulate by extrapolation from the animal studies that collapsing glomerulopathy or severe tubular injury or a combination of both may be the mechanism of acute kidney injury observed with this agent. This would be consistent with the observed severe acute kidney injury and proteinuria in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|